Nigral Glia In Parkinson'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Nigral glia comprise astrocytes, microglia, and oligodendrocytes that support the highly vulnerable dopaminergic neurons in the SNc. These glial cells undergo significant morphological and functional changes in PD, contributing to both protective and pathogenic processes.
- Metabolic support of dopaminergic neurons
- Glutamate uptake to prevent excitotoxicity
- Production of neurotrophic factors (GDNF, BDNF)
- Maintenance of blood-brain barrier integrity
- Reactive astrocytosis: Astrocytes become activated in the SNc of PD patients
- Reduced glutamate clearance: Impaired EAAT2 function leads to excitotoxicity
- Altered neurotrophic support: Decreased GDNF expression
- α-Synuclein transmission: Can receive α-synsynuclein from neurons via tunneling nanotubes
- Immune surveillance of the nigrostriatal system
- Phagocytic clearance of debris
- Support of neuronal homeostasis
- Chronic activation: Pro-inflammatory microglia surround dopaminergic neurons
- Pro-inflammatory cytokine release: TNF-α, IL-1β, IL-6
- NADPH oxidase activation: Increased ROS production
- Complement system activation: C1q-mediated synapse elimination
- DAM (Disease-Associated Microglia): Upregulation of TREM2, ApoE
- Myelin production for nigrostriatal axons
- Metabolic support of axons
- Ion homeostasis
- Oligodendrocyte loss: Reduced myelin basic protein in SNc
- Demyelination: Progressive loss of myelin integrity
- α-Synuclein accumulation: Oligodendrocytes can accumulate α-synuclein
- Impaired axonal transport: Consequences for dopaminergic signaling
- Microglia modulators: Minocycline, TGF-β pathway modulators
- Astrocyte reprogramming: GDNF delivery, astrocyte-to-neuron conversion
- Oligodendrocyte regeneration: PDGF-AA, OPC transplantation approaches
- GDNF and BDNF delivery to support glia-neuron interactions
- Gene therapy approaches targeting glial cells
- Post-mortem studies show 2-3x increased microglia density in SNc of PD patients
- PET imaging with TSPO ligands reveals microglial activation in early PD
- Animal models demonstrate that microglial depletion is neuroprotective
- Astrocyte-specific perturbations recapitulate PD-like pathology
The study of Nigral Glia In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Booth HDE, et al. (2017). The role of glial responses in Parkinson's disease. Acta Neuropathol Commun.
- Liddelow SA, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature.
- Van Kesteren RE, et al. (2021). Glial cells in Parkinson's disease. J Neural Transm.